REGISTRATION

Category1 Registration Type Fee
Club Member CSCC Members $150.00 plus applicable taxes
  Non-Members $175.00 plus applicable taxes
Single Roundtable CSCC Members $25.00 plus applicable taxes
  Non-Members $30.00 plus applicable taxes

All CSCC Education Roundtables will be held on Thursdays and will be one (1) hour in length.
Eastern Pacific Mountain Central Atlantic Newfoundland
ON, QC BC AB, SK* MB, ON (West) NB, NS, PE, Lab NL
11:30-12:30 08:30-09:30 09:30-10:30 10:30-11:30 12:30-13:30 13:30-14:30
14:00-15:00 11:00-12:00 12:00-13:00 13:00-1400 15:00-16:00 16:00-17:00
* SK - During daylight savings time; otherwise one hour later

Register HERE Today!

1Save today! Club members are entitled to join any or all of the Roundtables. Register once only and automatically receive an invitation for each Roundtable and access to the slides and recordings of past roundtables for the current year.

  • Registration is by pre-payment only using the online registration form.
  • Each registration is restricted to one (1) phone line; you may have as many participants using that line as you wish.  You are welcome to sign up more than one (1) phone line but each line must be a separate registration and payment. **COVID NOTE** During the pandemic when social distancing rules restrict gatherings, a group registration can apply to multiple lines and all members of the group can log in using their own line. If you are a member of a group please register without making the payment, and indicate your group name in the field provided.
  • Participants will be sent a 1-800 phone number for the audio and an internet url to view the slides.

2020-2021 SCHEDULE

  Date Time (Eastern) Presenter(s) Topic
1.  September 17, 2020 14:00-15:00     
   

cscc logo bilingual stacked100x80CSCC Special LectureshipRoche Logo

Sponsored by Roche

COVID-19 serology testing experience from Canadian clinical laboratories

  September 24, 2020 11:30-12:30  Zahraa Mohammed-Ali
Miranda Brun
Quality improvements from Canadian laboratories
Screening for Open Neural Tube Defects: Aligning with the Society of Obstetricians and Gynaecologists of Canada (SOGC) Guidelines 
3. October 8, 2020 14:00-15:00 Mathieu Provençal CSAN PRONTO a new era in mental health
4.  October 22, 2020 11:30-12:30  Jan Palaty

Ivan Blasutig

New tools for the qualitative and quantitiative analysis of fentanyl and its analogues
Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer
5. November 5, 2020 11:30-12:30 Ed Randell Autoverification
6. November 19, 2020 14:00-15:00 Francis Lin, Sarah Delaney What's New in POCT
7. December 3, 2020 11:30-12:30 TBA Reflection on a personal career
8. January 7, 2021      
9. January 21, 2021      
10.  February 4, 2021      
11.  February 18, 2021       
12. March 4, 2021      
13. March 18, 2021      
14. April 1, 2021      
15. April 15, 2021      
16. April 29, 2021      
17. May 13, 2021     Fellows-in-training presentations/Journal Clubs 

  

#4 Oct, 22, 2020 New tools for the qualitative and quantitative analysis of fentanyl and its analogues
Speaker: Jan Palaty, Clinical Biochemist, LifeLabs Medical Laboratories
Overview: Novel psychoactive substances (NPS) present a challenge for both point of care (POC) health care providers and the clinical laboratory. We will show the potential of mass spectrometry (MS) as a POC tool to provide quantitative information to patients on the contents of their street drugs. This targeted analysis can be informed by urine drug screening for hypothesized NPS in a larger population by searching for predicted metabolites and MS fragment ions. This strategy was used by a routine clinical lab to identify the novel analogues cyclopropyl-fentanyl in urine samples from substance use disorder clinics.
Learning Objectives: At the end of this presentation, participants will be able to:
1)  understand the principle of paper spray MS
2)  understand how precursor ion scanning can be used to search for NPS
3)  recognize pejorative terms such as "drugs of abuse" and "addict"
Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer
Speaker: Ivan M. Blasutig, Clinical Biochemist and Lab Director, CHEO - EORLA
Overview: The accurate quantification of immunoglobulin free light chains (FLC) in the serum is an important test in the management of plasma cell dyscrasias. The first assay introduced to detect serum FLCs was the Freelite assay introduced in 2001 and in 2011 N-latex FLC were introduced. This presentation will review our study published in Clinical Biochemistry in 2018 (Vol.51 p90-96) where we evaluate the performance of the N-Latex assay and assess agreement with the FreeLite assay. Effects of dilution and susceptibility to antigen excess will be emphasized.
Learning Objectives: At the end of this presentation, participants will be able to:
1)  better understand some of the inherent limitations of Free Light Chain measurement
2)  know the performance of the Siemens N-latex FLC assays on the BNII nephlelometer observed in our study
3)  have a better understanding of the challenges faced if switching Free Light Chain assays.
#3 Oct. 8, 2020 CSAN PRONTO a new era in mental health
Speaker: Mathieu Provencal, Clinical Biochemist, POCT supervisor, Maisonneuve-Rosemont Hospital, OPTILAB Montreal-CHUM 
Overview: Treatment-resistant Schizophrenia (TRS) is known to affects almost 30% of patients with a diagnosis of schizophrenia. Despite its unique efficacy in TRS, Clozapine is underprescribed in most countries, and that’s specifically true in Canada. One important reason for this includes a real fear of side effects. Another reason is that clozapine treatment comes with an inconvenient necessity of therapeutic blood monitoring (TDM). This explain that many who could benefit from clozapine actually do not. CSAN-PRONTO is a new and innovative POCT device enabling adequate TDM for patient initiating Clozapine treatment. 
Learning Objectives:  At the end of this session, participants will be able to:
1)  understand the context and issues around schizophrenia treatments
2)  discover the new POCT CSAN-PRONTO device
3)  learn about the ongoing pilot projects conducted in Montreal 
 #2 Sept. 24, 2020 Quality Improvements from Canadian Laboratories 
Speaker: Zahraa Mohammed-Ali, University of Toronto
Overview: This presentation is aimed at exploring the impact of reformulating a family medicine laboratory requisition as a quality improvement (QI) intervention to prevent unnecessary laboratory testing. First, we will introduce appropriate versus inappropriate laboratory testing, while highlighting solutions to improve laboratory testing. Then we will explain the PLAN-DO-STUDY-ACT (PDSA) strategy for QI projects using the reformulation of the family medicine laboratory requisition as an example. We will discuss the outcome, process and balancing measures employed as part of the study phase of the PDSA cycle to assess the effectiveness of our QI strategy. We will conclude by examining further steps and emphasizing the overall result and cost savings of our QI initiative.
Learning Objectives: At the end of this session, participants will be able to:
1) Review the importance of appropriate laboratory testing.
2) Understand the Plan-Do-Study-Act cycle in the context of reformulating a family medicine laboratory requisition to prevent unnecessary testing.
  Screening for Open Neural Tube Defects: Aligning with the Society of Obstetricians and Gynaecologists of Canada (SOGC) Guidelines
Speaker: Miranda Brun, Clinical Biochemist, Alberta Precision Laboratories, Edmonton 
Overview: The Society of Obstetricians and Gynaecologists of Canada (SOGC) recommends second trimester anatomical ultrasound for the detection of open neural tube defects. Screening by ultrasound should replace second trimester serum alpha fetoprotein screening for open neural tube defects except in settings when ultrasound examination is difficult. To adhere with these guidelines in Alberta, the second trimester screening team undertook a utilization project. A phased approach was implemented. First, the requisition was updated to list the specific indications for second trimester serum alpha fetoprotein screening with checkboxes. These indications are: i) no access to second trimester ultrasound, ii) pre-pregnancy BMI greater or equal to 35 kg/m2 , and iii) suspected neural tube defect by ultrasound. Following education and communication, directed feedback was utilized. For a period of two months, requisitions with no indication specified were accepted, and an informational bulletin regarding the indications for screening faxed to the ordering physician. At the end of this two months, requisitions with no indications were cancelled. This combined intervention resulted in a decrease of second trimester serum alpha fetoprotein screens from an average of 267/month in the six months prior to the change to <2/month after. Second trimester serum alpha fetoprotein screening for open neural tube defect remains available when clinically indicated. 
Learning Objectives: At the end of this session, participants will be able to:
1) Identify prenatal screening methods for open neural tube defects in pregnancy
2) Distinguish the screening method for open neural tube defects in pregnancy recommended by the Society of Obstetricians and Gynaecologists of Canada
3) Discuss potential tools to support implementation of guideline recommendations in screening programs